MannKind Corporation
30930 Russell Ranch Road
Suite 301
Westlake Village
California
91362
United States
Website: http://www.mannkindcorp.com/
398 articles about MannKind Corporation
-
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
3/11/2024
MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced initial meal challenge data from INHALE-3 that was presented by Dr. Irl B. Hirsch at the 17th International Conference on Advanced Technologies and Treatments for Diabetes in Florence on March 8th.
-
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
3/5/2024
MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced that new clinical data from the INHALE-3 study first meal challenge will be presented at the upcoming 17th International Conference on Advanced Technologies and Treatments for Diabetes in Florence on March 6-9.
-
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development UpdateConference Call to Begin Today at 5:00 p.m. (ET)
2/27/2024
We doubled our total revenues to nearly $200 million in 2023 and ended the year with a robust fourth quarter total revenue of $58 million
-
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
2/20/2024
MannKind Corporation will release its 2023 fourth quarter and full year financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM on Tuesday, February 27, 2024.
-
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
2/15/2024
MannKind Corporation announced that it has fully enrolled 305 patients living with type 1 or type 2 diabetes in its INHALE-1 study assessing efficacy and safety of inhaled insulin in the pediatric population.
-
MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
1/2/2024
MannKind Corporation announced that on December 27, 2023 it sold a 1% royalty in net sales of Tyvaso DPI® inhalation powder in exchange for up to $200 million, including the purchase price of $150 million and an additional potential milestone payment of up to $50 million.
-
MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
12/28/2023
MannKind Corporation announced that its Chief Executive Officer, Michael Castagna, PharmD, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 11:15 AM PST at the Westin St. Francis Hotel in San Francisco, California.
-
MannKind Corporation Reports 2023 Third Quarter Financial Results
11/7/2023
MannKind Corporation reported financial results for the quarter ended September 30, 2023.
-
MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
11/6/2023
MannKind Corporation announced that it has fully enrolled patients in INHALE-3, a Phase 4 clinical trial evaluating inhaled insulin versus usual care in adults living with type 1 diabetes.
-
MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023
10/31/2023
MannKind Corporation (Nasdaq: MNKD) will release its 2023 third quarter financial results and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM (Eastern Time) on Tuesday, November 7, 2023.
-
MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent
10/30/2023
MannKind Corporation announced a new patent issued by the United States Patent and Trademark Office covering clofazimine inhalation suspension, which is under development for the potential treatment of nontuberculous mycobacterial lung disease.
-
MannKind Corporation Announces Participation at Upcoming September 2023 Conferences
9/5/2023
MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced that it will be participating at upcoming conferences.
-
MannKind Corporation Reports 2023 Second Quarter Financial Results
8/7/2023
MannKind Corporation reported financial results for the quarter ended June 30, 2023.
-
MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference
8/1/2023
MannKind Corporation announced that its Chief Executive Officer, Michael Castagna, PharmD, will participate in one-on-one meetings at the 2023 Wedbush PacGrow Healthcare Conference on Tuesday, August 8, 2023 at the Lotte Palace in New York City.
-
MannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023
7/31/2023
MannKind Corporation will release its 2023 second quarter financial results and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM on Monday, August 7, 2023.
-
MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)
6/22/2023
MannKind Corporation announced that it is launching the INHALE-3 study to address the most important unmet need in adults living with T1D.
-
Governor Ned Lamont to Tour MannKind June 12 as It Reaches a Manufacturing Milestone
6/11/2023
MannKind Corporation will host Connecticut Governor Ned Lamont for a tour of its headquarters on Monday, June 12.
-
Dr. Burkhard Blank Joins MannKind as Executive Vice President of Research & Development and Chief Medical Officer
5/24/2023
MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced Burkhard Blank, MD, has joined the company as Executive Vice President, Research & Development and Chief Medical Officer.
-
MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
5/10/2023
MannKind Corporation announced that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023 at 2:05 pm at the InterContinental New York Barclay.
-
CORRECTION -- MannKind Corporation Reports 2023 First Quarter Financial ResultsConference Call to Begin Today at 5:00 p.m. (ET)
5/10/2023
MannKind Corporation reported financial results for the quarter ended March 31, 2023.